CareDx(US:CDNA)2026-02-24 22:32Financial Data and Key Metrics Changes - The company reported Q4 2025 revenue of $108 million, reflecting a 25% year-over-year growth [9][27] - Testing volume increased by 17% year-over-year, with approximately 53,000 tests delivered in Q4 [10][27] - Non-GAAP gross margin was maintained at 69%, with adjusted EBITDA of $7 million for the quarter [9][28] - Full-year 2025 revenue reached $379.8 million, a 14% increase year-over-year [30] - Adjusted EBITDA for the year was $31.7 million, representing a 14% increase over 2024 [31] Business Line Data and Key Metrics Changes - Testing services revenue for Q4 was $78 million, up 23% year-over-year, with kidney testing leading growth [10][27] - Patient and digital solutions revenue for Q4 was $17 million, a 47% increase year-over-year [15][28] - Lab products revenue for Q4 was $13 million, reflecting a 17% year-over-year increase [16][28] Market Data and Key Metrics Changes - The company noted that kidney transplant numbers were relatively flat year-over-year, but regulatory changes may provide a tailwind for testing services [11] - The heart transplantation market saw significant clinical evidence published, reinforcing the value of the company's testing solutions [12] Company Strategy and Development Direction - The company aims to advance its cell therapy pipeline, referred to as Transplant Plus, and has launched AlloHeme, an AI-powered NGS surveillance solution [18][20] - A focus on operational excellence and customer experience is central to the go-to-market strategy, with significant investments in Epic integrations [20][21] - The company is committed to expanding its evidence generation efforts to support clinical adoption and reimbursement [23][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's position for sustained growth and innovation, emphasizing the importance of evidence generation and interventional trials [40] - The anticipated impact of the draft Local Coverage Determination (LCD) is expected to negatively affect revenue by approximately $15 million in 2026 [32] Other Important Information - The company ended Q4 with approximately $200 million in cash equivalents and no debt, providing financial flexibility [9][30] - A transition in the CFO role was announced, with Keith Kennedy appointed as the new Chief Financial Officer [39] Q&A Session Summary Question: Volume guidance for the year seems low relative to the exit rate - Management is not assuming an increase in transplant procedural volume and believes it's too early to quantify the impact of Epic Aura [42][44] Question: Sustainability of growth in patient digital solutions - The company expects growth in patient and digital solutions to be in the range of 8%-12% for the upcoming year, with margins in the mid-sixties for software [45][46] Question: Guidance assumptions regarding the LCD impact - The guidance includes a $7.5 million revenue reduction due to the LCD, with additional factors affecting revenue per test [51][55] Question: Path to achieving higher reimbursement rates - The company is targeting a three-year goal to reach 2,000 tests, emphasizing the importance of streamlined operations and real-time information [64][66] Question: Commercial readiness for AlloHeme - A broad clinician education effort is planned, alongside submission for reimbursement, to ensure market readiness for AlloHeme [71][73] Question: Strength drivers in the digital solutions business - The company has gained market share in testing services, driven by a focus on solution selling and innovative products [78][80]